VALIUM Drug Patent Profile

« Back to Dashboard

Which patents cover Valium, and what generic alternatives are available?

Valium is a drug marketed by Roche and Waylis Therap and is included in two NDAs.

The generic ingredient in VALIUM is diazepam. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the diazepam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Valium

A generic version of VALIUM was approved as diazepam by MYLAN on September 4^th, 1985.

Summary for VALIUM

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	56
Clinical Trials:	49
Patent Applications:	4,538
Drug Prices:	Drug price information for VALIUM
What excipients (inactive ingredients) are in VALIUM?	VALIUM excipients list
DailyMed Link:	VALIUM at DailyMed

See drug prices for VALIUM

Recent Clinical Trials for VALIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Texas Scottish Rite Hospital for Children	PHASE2
University of Monastir	PHASE3
Mayo Clinic	Phase 1/Phase 2

See all VALIUM clinical trials

Pharmacology for VALIUM

Drug Class

Benzodiazepine

US Patents and Regulatory Information for VALIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	VALIUM	diazepam	INJECTABLE;INJECTION	016087-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Waylis Therap	VALIUM	diazepam	TABLET;ORAL	013263-006	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Waylis Therap	VALIUM	diazepam	TABLET;ORAL	013263-002	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Waylis Therap	VALIUM	diazepam	TABLET;ORAL	013263-004	Approved Prior to Jan 1, 1982	AB	RX	Yes	No

Expired US Patents for VALIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Waylis Therap	VALIUM	diazepam	TABLET;ORAL	013263-006	Approved Prior to Jan 1, 1982	4,316,897
Roche	VALIUM	diazepam	INJECTABLE;INJECTION	016087-001	Approved Prior to Jan 1, 1982	4,316,897
Waylis Therap	VALIUM	diazepam	TABLET;ORAL	013263-004	Approved Prior to Jan 1, 1982	4,316,897
Waylis Therap	VALIUM	diazepam	TABLET;ORAL	013263-002	Approved Prior to Jan 1, 1982	4,316,897

Valium Diazepam Market Dynamics, Patent Expiration, Generic Competition, and Financial Trajectory

Last updated: October 9, 2026

Valium, the Roche brand for diazepam, is a mature benzodiazepine with no meaningful U.S. market exclusivity. The drug was approved by the FDA in 1963, entered broad generic competition decades ago, and now generates limited direct value as an originator brand. Commercial activity is concentrated in low-cost generic diazepam tablets, oral solutions, injectable products, and rectal formulations. Demand remains supported by anxiety, muscle spasm, seizure, alcohol-withdrawal, and procedural-sedation uses, but controlled-substance restrictions, dependence concerns, and competition from newer therapies constrain growth. [1][2][3]

What is Valium and how large is the diazepam market?

Valium is diazepam, a long-acting benzodiazepine that enhances gamma-aminobutyric acid activity through the GABA-A receptor complex. The FDA label identifies indications including anxiety disorders, acute alcohol withdrawal, skeletal-muscle spasm, and adjunctive treatment for convulsive disorders. [1]

The commercial market now consists primarily of generic diazepam rather than branded Valium.

Market characteristic	Valium and diazepam position
Active ingredient	Diazepam
Original developer	Hoffmann-La Roche
U.S. approval	1963
Drug class	Benzodiazepine
U.S. controlled-substance schedule	Schedule IV
Main dosage forms	Tablets, oral solution, injection, rectal gel
Current U.S. market structure	Predominantly generic
Originator exclusivity	Expired
Major commercial constraint	Dependence, misuse, and long-term-use restrictions
Biosimilar exposure	None; diazepam is a small-molecule drug

Public company filings generally do not report Valium revenue as a separate product line. Roche reports pharmaceuticals by business division and major products rather than providing a current standalone Valium revenue figure. The economic value of the original brand is therefore best assessed through generic volume, channel pricing, manufacturing capacity, and regulatory status rather than Roche-reported sales. [4]

When did Valium lose patent and market exclusivity?

Valium lost practical U.S. exclusivity long ago. Diazepam was introduced in the early 1960s, and generic manufacturers entered after the relevant compound and product protections expired. The original U.S. diazepam patent is commonly identified as U.S. Patent No. 3,136,754, assigned to Hoffmann-La Roche. Its term did not create a current barrier to generic entry. [5]

Historical exclusivity timeline

Event	Approximate timing	Commercial effect
Diazepam discovered and developed by Roche	Late 1950s to early 1960s	Created the original Valium franchise
FDA approval of Valium	1963	Enabled U.S. commercial launch
Original compound patent period	1960s to early 1980s	Protected early branded sales
Generic diazepam availability	From the 1980s onward	Reduced branded pricing power
Hatch-Waxman generic pathway	1984 onward	Simplified abbreviated applications for generic products
Current market	2020s	Generic-dominated, fragmented supply

The key commercial point is that Valium has no remaining patent-based ability to delay an ordinary generic launch. Any current patent analysis must focus on specific manufacturers, formulations, delivery systems, or manufacturing processes rather than the original diazepam molecule.

What patents protect Valium and generic diazepam?

The original diazepam patent estate is expired. Current U.S. generic products may have historical patents associated with particular dosage forms or delivery technologies, but these do not restore exclusivity to the Valium brand.

Compound and product patents

The core diazepam compound patent is no longer enforceable as a market barrier. The Orange Book remains the principal FDA source for patents listed against approved drug products, including patents covering active ingredients, formulations, and approved methods of use. [6]

For a mature product such as diazepam, relevant current IP categories can include:

• Oral solid dosage-form formulation patents.
• Stabilized liquid formulation patents.
• Rectal-delivery systems.
• Injectable packaging or device claims.
• Manufacturing and purification processes.
• Narrow method-of-use patents.

These rights, where active, would generally protect a specific product or process. They would not automatically block all diazepam tablets or all diazepam products.

Orange Book status

Valium and diazepam should be evaluated by NDA number, dosage form, and current FDA listing rather than by brand name alone. The FDA’s Drugs@FDA database identifies the original Valium application as NDA 013263. Current generic products are approved under separate ANDAs. [7]

Because diazepam has been generic for many years, a standard tablet manufacturer generally faces no originator patent barrier comparable to the patent estates surrounding newer small-molecule medicines. An Orange Book review remains relevant for a specific product, but the broad market has no active core patent wall.

What is the FDA regulatory status of Valium?

Valium is FDA-approved, but it is not a new or expanding therapy. Its regulatory profile is mature and stable.

The FDA-approved label includes warnings concerning abuse, misuse, addiction, physical dependence, and withdrawal reactions. Diazepam is also subject to the FDA boxed warning applicable to benzodiazepines. Concurrent use with opioids can cause profound sedation, respiratory depression, coma, and death. [1]

The drug’s regulatory status creates both demand and commercial friction:

• Schedule IV controls restrict prescribing and dispensing.
• Long half-life and active metabolites increase accumulation risk.
• Older patients face greater risks of sedation, falls, cognitive impairment, and motor impairment.
• Long-term use is discouraged because of tolerance and dependence.
• Opioid-related regulatory scrutiny affects benzodiazepine prescribing.
• Institutional purchasers may prefer alternative agents with shorter duration or different safety profiles.

The FDA has not withdrawn diazepam from the market. Generic approvals continue to support tablet, solution, injection, and rectal products subject to manufacturing and labeling requirements.

What formulations are protected by diazepam patents?

Formulation and delivery products have a more defensible commercial position than standard tablets, but their protection is narrower.

Oral tablets and oral solution

Standard diazepam tablets are commoditized. Products are available in multiple strengths, commonly 2 mg, 5 mg, and 10 mg. Generic manufacturers compete primarily on price, supply reliability, contract terms, and pharmacy distribution.

Oral solutions can face greater manufacturing complexity than tablets because of solubility, stability, preservative, packaging, and dosing-device requirements. Those factors may create regulatory or technical barriers even when no broad patent prevents entry.

Rectal gel

Diazepam rectal gel is a specialized rescue product used for selected seizure emergencies. The commercial product historically associated with this delivery system is Diastat. Its value proposition is based on caregiver administration and rapid rescue use rather than routine daily therapy.

Rectal delivery can support product differentiation through:

• Device design.
• Administration mechanics.
• Stability and container-closure systems.
• Human-factors data.
• Labeling and use instructions.
• Manufacturing controls.

A competitor may avoid a device patent through a design change, but regulatory requirements and clinical-use familiarity can still slow substitution.

Injectable diazepam

Injectable diazepam is used in hospitals and emergency settings. It faces technical barriers involving solvent systems, precipitation risk, compatibility, packaging, and administration. The segment is more dependent on institutional procurement and supply continuity than on consumer brand loyalty.

How strong is the Valium patent estate?

The current Valium patent estate is weak as a source of commercial exclusivity because the core molecule and original branded product have been off patent for decades.

Patent-estate factor	Assessment
Core molecule protection	Expired
Original brand protection	No meaningful exclusivity
Standard tablet protection	Weak and generally nonexclusive
Specialized formulation protection	Potentially narrow
Device protection	Relevant for selected rescue products
Manufacturing trade secrets	Possible, but difficult to use against ordinary generic entry
Regulatory exclusivity	Expired
Litigation leverage	Low for the core product
Generic entry exposure	High

The main remaining barriers are operational rather than patent-based. These include FDA inspection outcomes, active pharmaceutical ingredient supply, validated manufacturing processes, controlled-substance compliance, drug-shortage dynamics, and the cost of maintaining low-volume dosage forms.

Which companies compete with Valium and generic diazepam?

The market is fragmented among generic manufacturers and specialty suppliers. Participants have included large generic companies such as Teva, Sandoz, Hikma, Endo-related businesses, and other ANDA holders, although the active supplier set can change through discontinuations, acquisitions, and FDA approval changes.

Competition occurs across four channels:

1. Retail tablets and oral solutions.
2. Hospital injectable products.
3. Specialty seizure-rescue products.
4. International branded and generic markets.

The principal therapeutic competitors are not direct substitutes in every indication. They include lorazepam, clonazepam, alprazolam, midazolam, chlordiazepoxide, phenobarbital, baclofen, and non-benzodiazepine treatments for anxiety, seizures, spasticity, and alcohol withdrawal.

Valium compared with other benzodiazepines

Product	Commercial distinction	Competitive pressure on diazepam
Lorazepam	Common inpatient and acute-care use; shorter acting	Strong in hospital and acute anxiety settings
Alprazolam	High use in panic and anxiety markets	Strong in outpatient anxiety treatment
Clonazepam	Long duration and seizure indications	Competes in chronic seizure and panic use
Midazolam	Procedural and emergency applications	Strong in procedural sedation
Chlordiazepoxide	Alcohol-withdrawal use	Direct indication-specific competitor
Diazepam	Long history, multiple dosage forms, muscle-spasm and withdrawal uses	Retains broad but mature utility

Diazepam’s long half-life supports some indications but reduces its attractiveness where clinicians prioritize shorter exposure and lower accumulation risk.

What generic entry risks exist for Valium?

Generic entry risk is already realized rather than prospective. The relevant question is not whether generic diazepam can enter, but whether a particular manufacturer can enter or expand without encountering product-specific barriers.

Standard tablet launch scenario

A new manufacturer of standard diazepam tablets would face:

• ANDA approval requirements.
• Bioequivalence testing.
• Controlled-substance registration.
• cGMP compliance.
• API qualification.
• Wholesale and retail contracting.
• Low expected pricing because several suppliers may already exist.

The likely launch economics are modest. A tablet entrant may gain volume only by undercutting price, securing a shortage-related opportunity, offering reliable supply, or serving a distribution niche.

Specialized formulation launch scenario

A rectal, liquid, or injectable entrant may achieve better pricing than a standard tablet supplier, but development costs and regulatory complexity are higher. Device patents, formulation patents, or exclusivity tied to a specific product may affect timing.

The commercial risk is asymmetric: specialized products have higher unit value, but demand is smaller and payer or institutional access can be concentrated.

What patent litigation and Paragraph IV challenges affect Valium?

There is no well-known current Paragraph IV campaign focused on the original Valium molecule. Paragraph IV litigation is primarily relevant when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or will not be infringed. [8]

For diazepam, historical generic entry and the age of the molecule mean that core-product Paragraph IV risk is largely resolved. Litigation could still arise around:

• A branded rescue-delivery system.
• A liquid formulation.
• A device or administration method.
• A newly approved indication.
• A manufacturing process.
• A reformulated product with active Orange Book patents.

A Paragraph IV filing against a specialized diazepam product could trigger a 30-month stay of FDA approval under Hatch-Waxman, subject to statutory conditions. That mechanism would affect the named product, not the entire diazepam category. [8]

No active settlement agreement materially controlling the broad U.S. diazepam market is publicly established in the core Valium context. Product-specific settlements must be assessed through court dockets, FDA listings, and the relevant patent records.

Does Valium face biosimilar risk?

No. Biosimilar risk does not apply because diazepam is a chemically synthesized small molecule, not a biologic. The relevant competitive threats are generic ANDA products, authorized generics, branded reformulations, and therapeutic substitutes.

The distinction matters commercially:

• Biosimilars compete through the biologics approval pathway.
• Diazepam generics compete through ANDAs.
• Interchangeability standards differ.
• Manufacturing scale and formulation design matter more than biologic similarity.
• The market has no originator biologic reference-product protection.

How does Valium compare with newer anxiety and seizure treatments?

Valium has a cost advantage but a weaker safety and growth profile than newer or differently targeted therapies.

Factor	Diazepam/Valium	Newer or alternative therapies
Price	Low for standard generic products	Often higher, especially branded products
Dependence risk	Material	Varies by class
Duration	Long acting	Often shorter or mechanism-specific
Generic competition	Extensive	Varies
Prescriber familiarity	Very high	Varies
Growth potential	Limited	Higher for differentiated therapies
Regulatory burden	Controlled-substance requirements	Depends on product
Patient segment	Acute and selected chronic uses	Often indication-specific

For anxiety, antidepressants and non-benzodiazepine agents reduce the role of diazepam in long-term treatment. For seizure rescue, specialized intranasal and buccal products compete with rectal diazepam by improving administration convenience. For alcohol withdrawal and muscle spasm, diazepam retains established clinical use.

What is the financial trajectory for Valium?

Valium’s financial trajectory is structurally mature and declining as an originator brand, with residual value in selected dosage forms and international markets.

Revenue profile

Roche does not publicly disclose a current standalone Valium revenue figure in its principal financial reporting. The brand should therefore not be treated as a separately reportable growth asset. [4]

The value chain is now divided among:

• Generic manufacturers earning low-margin volume revenue.
• Specialty suppliers selling differentiated delivery systems.
• Wholesalers and pharmacies operating under reimbursement pressure.
• Roche retaining historical brand recognition but limited direct economic control over generic diazepam.

Margin dynamics

Standard diazepam tablets are exposed to:

• Multiple approved suppliers.
• Pharmacy benefit-manager price pressure.
• Tender-based purchasing.
• API price changes.
• Manufacturing discontinuations.
• Low switching costs for pharmacies and wholesalers.

Margins can improve temporarily during shortages or supplier exits. Those gains are generally capacity-driven rather than patent-driven and may reverse when supply normalizes.

Revenue exposure by segment

Segment	Revenue outlook	Main driver
Branded Valium tablets	Low and declining	Loss of exclusivity and generic substitution
Generic tablets	Stable to declining pricing	Volume, contracts, supplier count
Oral solution	Niche	Formulation and supply reliability
Injectable diazepam	Mature institutional market	Hospital demand and supply continuity
Rectal rescue gel	Specialized	Clinical utility, device access, competition
International markets	Variable	Local brands, reimbursement, regulation

What geographic markets remain commercially relevant?

The United States is a mature generic market. International markets can retain branded diazepam sales under names such as Valium or local equivalents, but pricing, reimbursement, controlled-substance rules, and patent treatment vary by country.

Relevant geographic factors include:

• National reimbursement ceilings.
• Local generic-substitution rules.
• Controlled-drug import and distribution restrictions.
• Domestic manufacturing requirements.
• Reference-pricing systems.
• Country-specific formulation approvals.
• Counterfeit and diversion controls.

A U.S. patent conclusion should not be applied automatically to Europe, Japan, China, or emerging markets. The original compound protection has generally expired globally, but product, formulation, regulatory, and trademark rights can differ by jurisdiction.

What manufacturing and intellectual-property barriers affect diazepam?

The strongest current barriers are manufacturing and compliance barriers.

Manufacturing barriers

Diazepam suppliers must manage:

• Controlled-substance security.
• API sourcing and qualification.
• Solubility and precipitation control in injectable products.
• Stability of liquid formulations.
• Accurate low-dose tablet manufacturing.
• Packaging and serialization.
• FDA inspection and recall risk.
• Inventory requirements for hospital and emergency products.

These constraints can reduce the number of reliable suppliers even when many companies hold approvals.

Intellectual-property barriers

Potential IP barriers remain product-specific:

• Device claims for rectal or other rescue delivery.
• Formulation claims for liquid or injectable products.
• Method-of-use claims tied to a defined patient population.
• Process claims covering a particular manufacturing route.
• Trademark rights associated with Valium branding.

None of these categories recreates the broad exclusivity once attached to the diazepam molecule.

Key takeaways

• Valium is an FDA-approved diazepam brand introduced in 1963.
• The core diazepam patent estate is expired, and the U.S. market is generic-dominated.
• Roche does not publicly report current standalone Valium revenue.
• Standard diazepam tablets have low pricing power and limited growth potential.
• Rectal, liquid, and injectable formulations can retain niche value through delivery, manufacturing, or regulatory complexity.
• Paragraph IV risk is product-specific and is not a major barrier to ordinary generic diazepam entry.
• Diazepam has no biosimilar risk because it is a small molecule.
• Controlled-substance regulation, dependence warnings, and opioid co-use concerns limit prescribing expansion.
• Current commercial value depends more on supply reliability, dosage-form differentiation, and institutional contracts than on core patent rights.
• Generic manufacturers face high volume competition and modest margins, while specialized rescue products offer greater differentiation but smaller addressable markets.

FAQs about Valium patents, revenue, and generic competition

Is Valium still under patent in the United States?

No. The original diazepam compound and historical Valium protections expired long ago. Specific formulation or delivery patents may apply to individual products, but they do not protect all diazepam products.

Does Roche still make money from Valium?

Roche does not disclose a current standalone Valium revenue figure in its main financial reports. Any direct brand contribution is commercially minor compared with Roche’s current pharmaceutical portfolio.

Can a generic company launch diazepam without a Paragraph IV lawsuit?

Usually, a standard generic manufacturer can rely on expired core protections and pursue an ANDA without facing a meaningful core-product patent barrier. Specialized products may present separate listed-patent issues.

Which diazepam formulation has the strongest commercial position?

Specialized rescue and hospital formulations have more differentiation than ordinary tablets. Their strength comes from delivery systems, clinical workflow, manufacturing complexity, and supply reliability rather than broad molecule patents.

Is diazepam a declining drug?

Diazepam is declining as a branded growth product but remains commercially relevant as a low-cost generic and as a treatment for selected acute conditions, including alcohol withdrawal, muscle spasm, seizures, and procedural or emergency use.

References

1. U.S. Food and Drug Administration. (2020). Valium (diazepam) prescribing information. FDA.

2. U.S. Drug Enforcement Administration. (2024). Drug scheduling. U.S. Department of Justice.

3. National Library of Medicine. (2024). Diazepam drug label. DailyMed.

4. Roche Holding AG. (2024). Annual report 2023. Roche.

5. United States Patent and Trademark Office. (1964). U.S. Patent No. 3,136,754, 1,4-benzodiazepine derivatives. USPTO.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

7. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. FDA.

8. U.S. Food and Drug Administration. (2024). ANDA submissions: Patent certifications and 30-month stays. FDA.

DrugChatter Q&A for VALIUM

Generic valium names?
Why is valium called diazepam now?